Printer Friendly

THE COOPER COMPANIES REPORTS THIRD QUARTER RESULTS

 THE COOPER COMPANIES REPORTS THIRD QUARTER RESULTS
 NEW YORK, Sept. 14 /PRNewswire/ -- The Cooper Companies, Inc.


(NYSE: COO) today reported financial results for the third quarter and nine months ended July 31, 1992.
 For the three months ended July 31, 1992, the company reported a net loss applicable to common stock of $9.8 million or $.34 per share on net revenues of $19.3 million, compared with a net loss applicable to common stock of $4.2 million or $.16 per share on net revenues of $9.0 million in the third quarter of fiscal 1991.
 For the nine months fiscal year-to-date, net revenues were $41.4 million compared to $25.3 million for fiscal 1991. The company reported for the current nine-month period a net loss applicable to common stock of $9.5 million or $.35 per share, compared with a net loss applicable to common stock of $14.9 million or $.57 per share in the same period a year ago.
 "This quarter's results were seriously impacted by high legal costs related to certain of our divested businesses, the pending SEC and U.S. Attorney investigations, and a threatened proxy contest," said Arthur C. Bass, the company's acting chairman. "In addition, nearly half of the quarter's loss relates to reserves established for various lawsuits, primarily related to the divested businesses. While we are not pleased with these results, we are heartened that our ongoing operating businesses continue to demonstrate the recovery and growth evidenced by the first two quarters of this year.
 "Our newly acquired psychiatric hospital business, Hospital Group of America, is generating operating profits despite a very difficult environment; CooperSurgical's net sales of $4.1 million for the 1992 third quarter were more than twice those for the comparable 1991 period, although the business has yet to achieve profitability. For the nine months ended July 31, 1992, CooperSurgical reported net sales of $12.3 million compared to $4.7 million in the corresponding 1991 period. Although CooperVision's net sales were essentially flat for the fiscal year-to-date, its operating income dramatically improved to $1.1 million and $2.6 million for the third quarter and nine-month period, versus losses of $1.1 million and $3.5 million for the comparable periods in the prior year, respectively. This improvement reflects benefits of staff reductions and the success of our new frequent replacement lens, Preference(TM). CooperVision Pharmaceuticals, a development stage business, is performing on schedule as it continues the process of seeking Food and Drug Administration clearance to market Verapamil, a compound patented for use in the treatment of glaucoma, Phenyltrope, a proprietary pupillary dilating agent, and three other ophthalmic therapeutic products. In addition, CooperVision Pharmaceuticals is preparing to launch a line of branded generic ophthalmic pharmaceuticals in January 1993."
 As a result of the overall increase in revenues due to the psychiatric hospital acquisition and the growth of CooperSurgical, CooperVision's net sales for the quarter were only 36 percent of the company's consolidated net revenue, compared to 82 percent in the 1991 third quarter. In commenting on these results and noting the company's decreased dependence on its contact lens business, Bass added, "We are pleased that our efforts at restructuring and diversifying operations are proving to be successful. We hope that, in the long-term, the strength of our operating results will offset the high legal costs we are incurring to resolve litigation. If we are successful in those efforts, we are confident that shareholder value will increase."
 THE COOPER COMPANIES, INC. AND SUBSIDIARIES
 Statement of Consolidated Operations
 (In thousands, except per share figures)
 (Unaudited)
 Periods Ended Three Months Nine Months
 July 31 1992 1991 1992 1991
 Net service revenue $ 8,267 $ -- $ 8,267 $ --
 Net sales of product 11,068 8,970 33,129 25,314
 Net operating revenue 19,335 8,970 41,396 25,314
 Cost of products sold 4,499 4,066 13,989 11,049
 Operating expenses 22,807 12,629 42,105 36,378
 Settlement of disputes 4,495 -- 4,495 --
 Amortization of intangibles 168 257 558 689
 Investment income, net 6,066 4,423 18,652 9,386
 Gain on sales of assets and
 businesses, net -- -- 1,030 --
 Other income (expense), net (812) 164 (757) 711
 Interest expense 1,977 1,672 4,822 5,741
 Loss from cont. opers. bef.
 income taxes (9,357) (5,067) (5,648) (18,446)
 Provision for (benefit of)
 income taxes (1,245) 42 (112) 130
 Loss from cont. opers. bef.
 extraordinary items (8,112) (5,109) (5,536) (18,576)
 Loss on sale of discontinued
 operations, net of taxes (934) -- (2,300) --
 Loss before extraordinary items (9,046) (5,109) (7,836) (18,576)
 Extraordinary items (318) 1,553 -- 5,428
 Net loss (9,364) (3,556) (7,836) (13,148)
 Loss, dividend requirements on
 senior exchangeable redeemable
 restricted voting preferred stock 386 594 1,649 1,713
 Net loss applicable to com. stock (9,750) (4,150) (9,485) (14,861)
 Net inc. (loss) per com. shr.:
 Continuing operations $(.30) $(.22) $(.26) $(.78)
 Discontinued operations (.03) -- (.09) --
 Loss before extraordinary items (.33) (.22) (.35) (.78)
 Extraordinary items (.01) .06 -- .21
 Net loss per common share (.34) (.16) (.35) (.57)
 Avg. no. of com. shrs. outstdg. 28,279 25,923 26,747 25,860
 THE COOPER COMPANIES, INC. AND SUBSIDIARIES
 Consolidated Condensed Balance Sheet
 (In thousands)
 7/31/92 10/31/91
 (Unaudited)
 ASSETS
 Current assets:
 Cash and cash equivalents $ 40,128 $ 76,652
 Restricted cash 8,787 9,585
 Temporary investments 46,855 58,028
 Trade and other receivables, net 27,669 17,313
 Inventories 15,130 10,906
 Other current assets 3,663 1,373
 Total current assets 142,232 173,857
 Property, plant and equipment, net 36,286 3,593
 Intangibles, net 12,108 8,843
 Other assets 3,310 1,340
 Total $193,936 $187,633
 LIABILITIES AND STOCKHOLDERS' EQUITY
 Current liabilities:
 Short-term debt $ 3,846 $ 1,131
 Other current liabilities 47,119 50,542
 Total current liabilities 50,965 51,673
 Long-term debt:
 10-5/8 percent convertible subordinated
 reset debentures due 2005 48,494 48,012
 Other, less current installments 16,834 645
 Total 65,328 48,657
 Other non-current liabilities 14,210 15,601
 Total liabilities 130,503 115,931
 Stockholders' equity:
 Senior exchangeable redeemable restricted
 voting preferred stock, $.10 par value 15 60
 Preferred stock, $.10 par value -- --
 Common stock, $.10 par value 3,033 2,569
 Additional paid-in capital 181,108 182,567
 Accumulated deficit (117,956) (110,120)
 Translation adjustments 54 202
 Unamortized restricted stock award
 compensation (2,821) (3,576)
 Total stockholders' equity 63,433 71,702
 Total $193,936 $187,633
 -0- 9/14/92
 /NOTE TO EDITORS: Principal healthcare subsidiaries of The Cooper Companies, Inc. are CooperSurgical, Inc., CooperVision, Inc., CooperVision Pharmaceuticals, Inc. and Hospital Group of America, Inc. Today, Cooper Companies also is filing with the Securities and Exchange Commission a Form 10-Q reporting on its three and nine month results in greater detail. Copies of the Form 10-Q can be obtained upon request to the company./
 /CONTACT: Marisa A. Heine or Peter C. Harkins of D.F. King & Co., Inc., 212-269-5550, for the Cooper Companies/
 (COO) CO: Cooper Companies, Inc. ST: New York IN: MTC SU: ERN


SM-PS -- NY079 -- 9356 09/14/92 18:08 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 14, 1992
Words:1216
Previous Article:MICRODISK SERVICES TO ACQUIRE EXMARK
Next Article:APPRAISER SENTENCED TO 37 MONTHS IN LAND FLIP SCHEME
Topics:


Related Articles
COOPER DEVELOPMENT REPORTS THIRD QUARTER RESULTS
THE COOPER COMPANIES REPORTS THIRD QUARTER RESULTS
Cooper Cameron Expects Third Quarter Earnings to Be Flat With Prior Year, Fourth Quarter to Be Down Slightly From Year Ago.
Cooper Reports Third-Quarter Share Earnings of $.81.
Cooper Industries' Third Quarter Per Share Earnings Up 10 Percent; Strong Top-Line Growth in Electrical Products Drives Positive Results.
Cooper Tire & Rubber Company Adjusts Third Quarter Expectations.
Cooper Tire & Rubber Company Reports Third Quarter Results.
Cooper Industries Reports Third-Quarter Earnings of 68 Cents Per Share.
Cooper Tire & Rubber Company Reports Third Quarter Results.
Cooper-Standard Automotive Announces Third Quarter Results.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters